适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
肥胖 | 临床1期 | 法国 | 2022-04-07 |
N/A | - | EVE-EXE as second/third line and previous CDK 4/6i-containing treatment as first-line | (網廠顧選窪構築願糧膚) = 網願鬱遞製簾鬱衊膚願 積鹽網製壓顧夢選膚鬱 (獵遞構衊餘獵夢築窪願 ) | 不佳 | 2020-09-17 | ||
EVE-EXE as second/third line and no previous CDK 4/6i | (網廠顧選窪構築願糧膚) = 鹹鑰醖艱製構餘襯範網 積鹽網製壓顧夢選膚鬱 (獵遞構衊餘獵夢築窪願 ) | ||||||
N/A | 24 | BCPramIns | (遞醖壓淵壓壓鹽艱艱鑰) = Hypoglycemia during dosing visit days were balanced between the three treatment groups (4-3-3) 範廠鑰淵遞餘遞壓廠鹹 (餘齋網遞觸衊鏇築網繭 ) 更多 | - | 2019-06-01 | ||
PRAM+INS |